Research Topics
Species | Jesus F San-MiguelSummaryAffiliation: Universidad de Salamanca Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneJesus F San-Miguel
Servicio de Hematologia, Hospital Universitario de Salamanca, CIC, IBMCC, Spain
Clin Lymphoma Myeloma Leuk 11:38-43. 2011..In both trials the treatment was continued until disease progression or unacceptable toxicity. We conducted a subanalysis to determine if continuing therapy after achieving≥partial response (PR) improved survival...- Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJesus F San Miguel
Hospital Universitario Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
J Clin Oncol 31:448-55. 2013.... 
Genomic analysis of high-risk smoldering multiple myelomaLucía López-Corral
Servicio de Hematología del Hospital Universitario de Salamanca y Centro de Investigación del Cáncer IBMCC USAl CIC, Universidad de Salamanca, Salamanca, Spain
Haematologica 97:1439-43. 2012..These findings suggest that gene expression profiling is a valuable technique to identify smoldering myeloma patients with high risk of progression. (Clinical Trials NCT00443235)...- Multiple myeloma: treatment evolutionJesus F San Miguel
Servicio de Hematologia, Hospital Universitatio de Salamanca, CIC, IBMCC USAL CSIC, Spain
Hematology 17:S3-6. 2012.... - The DAC system and associations with multiple myelomaEnrique M Ocio
University Hospital of Salamanca, Salamanca, Spain
Invest New Drugs 28:S28-35. 2010..This has prompted the development of combinations such as the one with bortezomib or lenalidomide and dexamethasone, which have already been taken into the clinics with positive preliminary results... - Risk stratification in the era of novel therapiesJesús San-Miguel
Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, Salamanca 37007, Spain
Cancer J 15:457-64. 2009.... - Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaJesus F San Miguel
Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
N Engl J Med 359:906-17. 2008..This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy... - Individualizing treatment of patients with myeloma in the era of novel agentsJesús San-Miguel
Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, 37007 Salamanca, Spain
J Clin Oncol 26:2761-6. 2008.... - Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 studyJ F San-Miguel
Department of Hematology, Hospital Universitario CIC Universidad de Salamanca CSIC, Salamanca, Spain
Leukemia 22:842-9. 2008..These results indicate that bortezomib is active and well tolerated in patients with relapsed MM with varying degrees of renal insufficiency. Efficacy/safety were not substantially affected by severe-to-moderate vs no/mild impairment... 
Conventional diagnostics in multiple myelomaJesus F San Miguel
Servicio de Haematología, Hospital Universitario de Salamanca, Paseo de San Vicente 58 182, 37007, Salamanca, Spain
Eur J Cancer 42:1510-9. 2006..In addition, possible technical pitfalls inherent to each technique will be analysed...- A practical update on the use of bortezomib in the management of multiple myelomaJesus San Miguel
Hematology Department, Hospital Clinico Universitario de Salamanca, Servicio de Hematologia, Paseo de San Vicente 58, Salamanca E 37007, Spain
Oncologist 11:51-61. 2006..Information is given on the practical management of the most common adverse events, including peripheral neuropathy and thrombocytopenia, and the use of bortezomib in renal and hepatic impairment... - Analysis of methylation pattern in multiple myelomaJesús San-Miguel
Servicio de Hematologia, Hospital Universitario de Salamanca, Centro de Investigacion del Cancer, Universidad de Salamanca, Salamanca, Spain
Acta Haematol 114:23-6. 2005..Multiple myeloma remains an incurable disease, so new treatment strategies are needed to improve the outcome of patients... - Prognostic features of multiple myelomaJesus F San Miguel
Department of Hematology, University Hospital of Salamanca, Paseo de San Vicente, 58 182, Salamanca 37007, Spain
Best Pract Res Clin Haematol 18:569-83. 2005.... - Myeloma: update on supportive care strategiesJesus F San Miguel
Department of Hematology, University Hospital of Salamanca, Paso de San Vicente 52 182, 37007 Salamanca, Spain
Curr Treat Options Oncol 4:247-58. 2003..However, in MM, several specific adjuvant therapies have also been introduced (eg, bisphosphonates and erythroid-stimulating factors), which have conferred a key role to supportive therapy in the general treatment of patients with MM... - In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaEnrique M Ocio
Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca P San Vicente, 58 182, 37007 Salamanca, Spain
Haematologica 95:794-803. 2010..We explored the antimyeloma activity of triple combinations of these well-established schemes with panobinostat, a novel deacetylase inhibitor with a multi-targeted profile... - The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva
Hospital Universitario de Salamanca, Salamanca, Spain
Blood 114:4369-72. 2009..This trial was registered at www.clinicaltrials.gov as NCT00560053... - Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDsEnrique M Ocio
University of Salamanca, University Hospital and Cancer Research Center, Department of Hematology, Salamanca, Spain
Expert Opin Investig Drugs 21:1075-87. 2012.... - Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trialMaria Victoria Mateos
Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer Universidad de Salamanca Consejo Superior de Investigaciones Científicas, Salamanca, Spain
Blood 120:2581-8. 2012..In summary, these maintenance regimens result in a significant increase in CR rate, remarkably long PFS, and acceptable toxicity profile. The trial is registered at www.clinicaltrials.gov as NCT00443235... - Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patientsMaria E Sarasquete
Servicio de Hematologia, Hospital Universitario, Centro de Investigación del Cáncer IBMCC USAL CSIC, Salamanca, Spain
Haematologica 96:468-71. 2011..02). By contrast, no differences in the expression of Drosha among these groups of patients were observed. Our data suggest that Dicer expression may play an important role in the progression and prognosis of monoclonal gammopathies... - New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findingsEnrique M Ocio
Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
Lancet Oncol 9:1157-65. 2008..Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents... - Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical valueMaria Belen Vidriales
Department of Hematology, University Hospital, Salamanca, Spain
Blood 101:4695-700. 2003.... - Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage responseEnrique Colado
Centro de Investigacion del Cancer, IBMCC CSIC Universidad de Salamanca, Salamanca, Spain
Haematologica 96:687-95. 2011..We investigated the antileukemic activity and mechanism of action of zalypsis, a novel alkaloid of marine origin... - Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML)Jesus F San-Miguel
Department of Haematology, University Hospital of Salamanca, Paseo de San Vicente 58 182, 37007 Salamanca, Spain
Best Pract Res Clin Haematol 15:105-18. 2002..Although reported data in the literature are still scanty, several authors have shown that this technique could be used for the prognostic evaluation of AML patients, when immunophenotypic evaluation is applied after induction therapy... - Immunologic monitoring in adults with acute lymphoblastic leukemiaMaria Belen Vidriales
Hematology Department, University Hospital of Salamanca, Paseo de San Vicente 58 182, 37007 Salamanca, Spain
Curr Oncol Rep 5:413-8. 2003.... - Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometryRoberto J Pessoa de Magalhães
Hospital Universitario de Salamanca, Salamanca, Spain
Haematologica 98:79-86. 2013.... - Minimal residual disease monitoring by flow cytometryMaría B Vidriales
Department of Haematology, University Hospital, Paseo de San Vicente 58 182, 37007, Salamanca, Spain
Best Pract Res Clin Haematol 16:599-612. 2003..Current knowledge indicates that MRD studies using well-tested methodologies are clinically useful and should be incorporated into the clinical management of patients with acute leukaemia... - Influence of the different CD34+ and CD34- cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donorsPablo Menendez
Servicio General de Citometria, Departamento de Medicina and Centro de Investigaciones del Cáncer, Universidad de Salamanca, Spain
Br J Haematol 119:135-43. 2002..However, they also strongly impair clinical outcome by increasing the incidence of GVHD... - Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaksEnrique M Ocio
Centro de Investigacion del Cancer, Instituto de Biologia Molecular y Celular del Cancer Centro de Superior de Investigaciones Cientificas Universidad de Salamanca, Spain
Blood 113:3781-91. 2009..The potent in vitro and in vivo antimyeloma activity of Zalypsis uncovers the high sensitivity of tumor plasma cells to DSBs and strongly supports the use of this compound in MM patients... - Limbus damage in ocular graft-versus-host diseaseRebeca Lorenzo Pérez
Servicio de Oftalmologia, Universidad de Salamanca, Salamanca, Spain
Biol Blood Marrow Transplant 17:270-3. 2011..Our results represent a major finding that allows us to define a model for evaluating new therapeutic strategies for treating ocular GVHD prior to their use in clinical setting... - Bone remodelation markers are useful in the management of monoclonal gammopathiesJose M Hernandez
Department of Hematology, Hospital General of Segovia, Spain
Hematol J 5:480-8. 2004..01). BRM and BFM, especially the ratios, are useful in the evaluation of bone lesions in patients with monoclonal gammopathies... - Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myelomaBruno Paiva
Hospital Universitario de Salamanca, Salamanca, Spain
J Clin Oncol 29:1627-33. 2011..To investigate the impact of immunophenotypic response (IR) versus complete response (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR) in elderly patients with multiple myeloma (MM) treated with novel agents... - The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotypeEnrique Colado
Department of Haematology, Hospital Universitario de Salamanca, Salamanca, Spain
Haematologica 93:57-66. 2008..We investigated the effects of bortezomib on the growth and survival of AML cells...